Effect of High-Dose Drug-Coated Balloon Repetition After Drug-Coated Balloon Failure

被引:2
|
作者
Tomoi, Yusuke [1 ]
Takahara, Mitsuyoshi [2 ]
Soga, Yoshimitsu [1 ]
Hirano, Taichi [1 ]
Tsunoda, Kazuki [1 ]
Katsuki, Tomonori [1 ]
Ando, Kenji [1 ]
机构
[1] Kokura Mem Hosp, Dept Cardiol, 3-2-1 Asano,Kokurakita Ku, Kitakyushu 8020001, Japan
[2] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Japan
关键词
peripheral artery disease; drug-coated balloon; restenosis; RESTENOSIS; ANGIOPLASTY; OUTCOMES; DISEASE;
D O I
10.1177/15266028231214167
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: Although the optimal treatment for femoropopliteal (FP) drug-coated balloon (DCB) restenosis lesions remains debatable, the effectiveness of DCB repetition for DCB restenosis has been reported. However, the optimal DCB repetition strategy is not yet established. Thus, this study aimed to compare the clinical outcomes of high-dose DCB repetition with those of low-dose DCB repetition for FP DCB restenosis lesions. Materials and Methods: This single-center, observational study used a clinical database of 677 consecutive patients undergoing FP endovascular intervention for symptomatic peripheral artery disease between December 2018 and December 2021. Of these patients, 89 cases treated with DCB repetition for FP DCB restenosis lesions were analyzed. The primary endpoint was recurrent restenosis (re-restenosis) and the secondary endpoints were recurrent target-lesion revascularization (TLR), re-occlusion, and major adverse limb events (MALE) obtained using propensity score matching. Interaction analysis was also performed to explore the effects of the baseline characteristics on the association between high- and low-dose DCB with restenosis risk. Results: After propensity score matching, high-dose DCB demonstrated a significantly higher freedom from re-restenosis compared with low-dose DCB repetition at 1 year (90.4% vs 40.9%, p=0.034). In addition, freedom from re-TLR and MALE at 1 year was significantly higher in the high-dose DCB group (95.0% vs 53.3%, p=0.025; 95.0% vs 54.7%, p=0.025, respectively). Conversely, freedom rates from re-occlusion were not significantly different between the 2 groups (100.0% vs 84.0%, p=0.99). No baseline characteristics or perioperative outcomes had any significant interaction effect on the association of high-dose DCB versus low-dose DCB with restenosis risk. Conclusion: For FP DCB restenosis lesions, high-dose DCB repetition offered more favorable outcomes than low-dose DCB repetition. Clinical Impact This study revealed that for femoropopliteal drug-coated balloon (DCB) restenosis lesions, high-dose DCB repetition obtained more favorable outcomes than low-dose DCB repetition. In addition, there was no significant interaction effect on the association of high- versus low-dose DCB with re-restenosis risk for the baseline characteristics and perioperative outcomes. This finding might be also a reason for choosing high-dose DCB repetition for FP DCB restenosis lesions in daily clinical practice.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Clinical Outcomes of Repetition of Drug-Coated Balloon for Femoropopliteal Restenosis After Drug-Coated Balloon Treatment
    Jang, Shih-Jung
    Chou, Hsin-Hua
    Juang, Jyh-Ming Jimmy
    Hsieh, Chien-An
    Duan, De-Min
    Huang, Hsuan-Li
    Ko, Yu-Lin
    CIRCULATION JOURNAL, 2017, 81 (07) : 993 - 998
  • [2] Drug-coated percutaneous balloon catheters
    La Berge, Martine, 1600, Begell House Inc. (42): : 3 - 4
  • [3] Drug-Coated Balloon "Scoring to Win"
    de la Torre Hernandez, Jose M.
    Puri, Rishi
    Alfonso, Fernando
    JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (13) : 1341 - 1343
  • [4] Drug-coated balloon superior to standard balloon angioplasty
    Karina Huynh
    Nature Reviews Cardiology, 2017, 14 : 383 - 383
  • [5] Does a Drug-Coated Balloon Accelerate Neoatherosclerosis?
    Mori, Hiroyoshi
    Sone, Hiromoto
    Wada, Daisuke
    Takei, Yosuke
    Tashiro, Kazuma
    Sasai, Masahiro
    Sato, Tokutada
    Suzuki, Hiroshi
    CJC OPEN, 2020, 2 (04) : 306 - 307
  • [6] Stellarex drug-coated balloon: a technology evaluation
    Nerla, Roberto
    Castriota, Fausto
    Cremonesi, Alberto
    Micari, Antonio
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (09) : 1181 - 1188
  • [7] Is the enthusiasm for Drug-Coated balloon technology justified?
    Basavarajaiah, Sandeep
    Bhatia, Gurbir
    Cortese, Bernardo
    Khialani, Bharat
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2024,
  • [8] Drug-coated balloon in peripheral artery disease
    Shanmugasundaram, Madhan
    Murugapandian, Sangeetha
    Huu Tarn Truong
    Lotun, Kapildeo
    Banerjee, Subhash
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2019, 20 (04) : 338 - 343
  • [9] State of the art: balloon catheter technologies - drug-coated balloon
    Alfonso, Fernando
    Scheller, Bruno
    EUROINTERVENTION, 2017, 13 (06) : 680 - 695
  • [10] Clinical Outcomes of Atherectomy Plus Drug-coated Balloon Versus Drug-coated Balloon Alone in the Treatment of Femoropopliteal Artery Disease
    Cha, Jung-Joon
    Lee, Jae-Hwan
    Ko, Young-Guk
    Roh, Jae-Hyung
    Yoon, Yong-Hoon
    Lee, Yong-Joon
    Lee, Seung-Jun
    Hong, Sung-Jin
    Ahn, Chul-Min
    Kim, Jung-Sun
    Kim, Byeong-Keuk
    Choi, Donghoon
    Hong, Myeong-Ki
    Jang, Yangsoo
    KOREAN CIRCULATION JOURNAL, 2022, 52 (02) : 123 - 133